In the past week, TOI stock has gone down by -30.77%, with a monthly decline of -46.98% and a quarterly plunge of -44.95%. The volatility ratio for the week is 16.22%, and the volatility levels for the last 30 days are 14.05% for Oncology Institute Inc The simple moving average for the past 20 days is -38.90% for TOI’s stock, with a -77.57% simple moving average for the past 200 days.
Is It Worth Investing in Oncology Institute Inc (NASDAQ: TOI) Right Now?
The stock has a 36-month beta value of 0.56. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TOI is 36.80M, and at present, short sellers hold a 0.67% of that float. On November 18, 2024, the average trading volume of TOI was 146.08K shares.
TOI) stock’s latest price update
The stock of Oncology Institute Inc (NASDAQ: TOI) has decreased by -23.47 when compared to last closing price of 0.24.Despite this, the company has seen a loss of -30.77% in its stock price over the last five trading days. seekingalpha.com reported 2024-11-13 that The Oncology Institute, Inc. (NASDAQ:TOI ) Q3 2024 Earnings Conference Call November 13, 2024 5:00 PM ET Company Participants Mark Hueppelsheuser – General Counsel Daniel Virnich – CEO Rob Carter – CFO Operator Good afternoon and welcome to The Oncology Institute’s Third Quarter 2024 Earnings Conference Call. Today’s call is being recorded, and we have allocated one hour for prepared remarks and Q&A.
Analysts’ Opinion of TOI
Many brokerage firms have already submitted their reports for TOI stocks, with Jefferies repeating the rating for TOI by listing it as a “Buy.” The predicted price for TOI in the upcoming period, according to Jefferies is $2.50 based on the research report published on February 26, 2024 of the current year 2024.
Guggenheim, on the other hand, stated in their research note that they expect to see TOI reach a price target of $7. The rating they have provided for TOI stocks is “Buy” according to the report published on September 14th, 2022.
Jefferies gave a rating of “Buy” to TOI, setting the target price at $10 in the report published on August 15th of the previous year.
TOI Trading at -40.93% from the 50-Day Moving Average
After a stumble in the market that brought TOI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.80% of loss for the given period.
Volatility was left at 14.05%, however, over the last 30 days, the volatility rate increased by 16.22%, as shares sank -51.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.98% lower at present.
During the last 5 trading sessions, TOI fell by -30.77%, which changed the moving average for the period of 200-days by -91.51% in comparison to the 20-day moving average, which settled at $0.2946. In addition, Oncology Institute Inc saw -91.18% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TOI starting from Havencrest Healthcare Partners, who sale 8,637 shares at the price of $2.12 back on Jan 29 ’24. After this action, Havencrest Healthcare Partners now owns 0 shares of Oncology Institute Inc, valued at $18,310 using the latest closing price.
Havencrest Healthcare Partners, the 10% Owner of Oncology Institute Inc, sale 24,915 shares at $2.30 during a trade that took place back on Jan 24 ’24, which means that Havencrest Healthcare Partners is holding 27,498 shares at $57,304 based on the most recent closing price.
Stock Fundamentals for TOI
Current profitability levels for the company are sitting at:
- -0.17 for the present operating margin
- 0.36 for the gross margin
The net margin for Oncology Institute Inc stands at -0.17. The total capital return value is set at -0.48. Equity return is now at value -131.66, with -28.92 for asset returns.
Based on Oncology Institute Inc (TOI), the company’s capital structure generated 0.89 points at debt to capital in total, while cash flow to debt ratio is standing at -0.53. The debt to equity ratio resting at 7.94. The interest coverage ratio of the stock is -7.68.
Currently, EBITDA for the company is -70.45 million with net debt to EBITDA at -1.19. When we switch over and look at the enterprise to sales, we see a ratio of 0.24. The receivables turnover for the company is 6.91for trailing twelve months and the total asset turnover is 2.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.49.
Conclusion
To sum up, Oncology Institute Inc (TOI) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
